Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenomics of Thiazolidinediones

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 35-64~* BMI: ≥ 25 and ≤ 40~Exclusion Criteria:~* Pregnancy as determined by urine pregnancy test Breast-feeding, or planning to become pregnant during the study~* Physical dimensions exceeding the limits of any equipment used~* Stage III or greater congestive heart failure~* Symptomatic peripheral vascular disease~* Stroke~* Severe hypertension (\>170/100 mmHg)~* Anemia (Hgb and Hct \< normal reference range)~* Receiving treatment for thyroid, pituitary, kidney or liver disease (except controlled thyroid hormone replacement)~* History of diabetes (as told by doctor, or taking diabetic medications Fasting glucose value diagnostic for diabetes 2-h oral glucose tolerance test diagnostic for diabetes~* Rheumatoid arthritis~* History of wrist, hip or leg fracture after the age of 45~* History of kidney stones~* Medications that the investigator judges will make interpretation of the results difficult or increase the risk of participation (e.g. anticoagulants)~* Any disease or condition that the investigator judges will affect bone metabolism or make interpretation of the results difficult or increase the risk of participation (e.g. anemia, cardiac decompensation, intolerance to pioglitazone, lidocaine, or other agents used)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Pioglitazone (Actos) (Type: EXPERIMENTAL): Participants will have metabolism studies to consist of outpatient X-ray and MR measurements of bone density and body composition, metabolic testing (intravenous glucose tolerance test), and muscle and adipose tissue biopsies. Blood will also be drawn for genetic testing and for microarray studies of leukocytes. Upon completion of the above studies, the participant will begin pioglitazone therapy. Every 4 weeks throughout the drug intervention, glycemic control, lipoprotein profile, and weight will be monitored. After 12 weeks of pioglitazone therapy, the X-ray and MR measurements of body composition, the biopsies, microarray studies for leukocytes and the metabolic tests will be repeated.

Based on this trial design, predict the completion outcome and termination type (if applicable).